The journal Prescrire analysed the medicines that were
introduced to the French market between 2006 and 2011, declared that only one
medicine of significant therapeutic interest was brought to the market.
Oncologists from fifteen countries recently denounced the
excessive prices of cancer treatments, which are necessary to save the lives of
the patients, and urged that moral implications should prevail; according to
them, of the 12 cancer treatments approved in 2012 by the United States Food
and Drug Administration, 11 cost more than 100,000 dollars per patient per
year.
In 2014, a number of European countries, including France
and Spain, spent many months negotiating with the company Gilead on the price
of a new medicine for hepatitis C known as Solvaldi. The price fixed by Gilead
was 56,000 Euros per patient for a twelve-week treatment, or 666 Euros per
tablet. According to Le Monde the price of each tablet was 280 times more than
the production cost. In France, it is calculated that 250,000 patients should
receive this medicine, the cost of which would represent 7 per cent of the
annual state medicine budget.
No comments:
Post a Comment